Studies about the safety and efficacy of metformin in GDM show that metformin is associated with a lower risk of gestational hypertension, pre-eclampsia, macrosomia, and neonatal hypoglycemia compared with insulin therapy [22,23,24], even though the glycemic control profiles are found to be comparable [25,26]. The gene discussed is INS; the disease is preeclampsia.